Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | CGC-11047 | Polyamine analogue | 9254.124 | uM | 26.98710 | 1000.00000 | 0.1010 | -0.7823 | 0.2607 | 0.2991 | 0.7092 | 0.8067 | ||
| HCC1395 | TNBC | Basal B | CGC-11047 | Polyamine analogue | 9258.026 | uM | 0.44087 | 35.50130 | -1.0000 | -1.0000 | 0.2503 | 0.8247 | 0.7494 | 0.5632 | ||
| HCC1395 | TNBC | Basal B | CGC-11047 | Polyamine analogue | 7813.018 | uM | 67.35460 | 248.74160 | -0.9987 | -1.0000 | 0.8409 | 0.6221 | 0.8654 | 0.8420 | ||
| MDA-MB-134-VI | HR+ | Luminal | Nelfinavir | 12662.174 | uM | 8.54930 | 13.26020 | -0.8199 | -1.0000 | 2.5030 | 0.1789 | 0.9953 | 1.6130 | |||
| BT-474 | HER2amp | Luminal | CGC-11047 | Polyamine analogue | 9157.034 | uM | 162.90980 | 696.84330 | -0.9646 | -1.0000 | 0.7559 | 0.4501 | 0.8634 | 1.0593 | ||
| HCC1143 | TNBC | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 7809.016 | uM | inf | inf | 0.3854 | 0.3854 | 0.0000 | 0.1556 | 0.5101 | 1.6622 | ||
| SUM1315MO2 | TNBC | Basal B | Methylglyoxal | 13520.184 | uM | 567.6950 | 786.82260 | -0.9992 | -0.9966 | 3.3588 | 0.6425 | 0.9974 | 0.6738 | |||
| BT-474 | HER2amp | Luminal | CGC-11047 | Polyamine analogue | 9163.026 | uM | 1.16670 | 17.90580 | -1.0000 | -1.0000 | 0.4023 | 0.8897 | 0.9004 | 0.3738 | ||
| HCC1143 | TNBC | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 7810.016 | uM | 159.09790 | 169.8520 | 0.4286 | -0.1925 | 4.9796 | -0.0031 | 0.9506 | 0.9032 | ||
| 184A1 | NM | Basal | Glycyl-H-1152 | ROCK2 | 12509.169 | uM | inf | inf | 0.8820 | 0.8820 | 0.0000 | 0.0673 | 0.0092 | 1.5064 | ||
| 21MT-1 | HER2amp | - | Mebendazole | 13719.174 | uM | 31.97060 | 77.55140 | 0.0875 | -1.0000 | 1.2398 | 0.1610 | 0.8782 | 0.8124 | |||
| CAMA-1 | HR+ | Luminal | Torkinib | 15348.211 | uM | 0.00176 | 0.01477 | -0.8919 | -0.9141 | 0.4883 | 1.1876 | 0.9886 | 0.7490 | |||
| AU565 | HER2amp | Luminal | Ibandronate | FDPS | 10880.143 | uM | 190.49250 | 139.95740 | 0.2035 | 0.1860 | 1.5087 | 0.1480 | 0.9763 | 1.6077 | ||
| MCF12A | NM | Basal B | Pertuzumab | 7489.102 | mg/ml | inf | 125.00000 | 0.8728 | 0.5007 | 0.2455 | 0.0447 | 0.7417 | 2.4234 | |||
| 21MT-1 | HER2amp | - | Methylglyoxal | 13719.184 | uM | 680.32080 | 999.99990 | -0.9954 | -0.9645 | 2.7899 | 0.6345 | 0.9961 | 0.7600 | |||
| MDA-MB-415 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 7897.016 | uM | 32.84980 | 48.58170 | -0.9480 | -1.0000 | 2.8076 | 0.2266 | 0.9871 | 0.7300 | ||
| SUM225CWN | HER2amp | Basal A | Torkinib | 15403.211 | uM | 0.02304 | 0.20245 | -0.6514 | -0.8008 | 0.4399 | 0.7911 | 0.9881 | 0.7553 | |||
| MCF12A | NM | Basal B | Ribavirin | 15354.211 | uM | inf | inf | 0.7146 | 0.7146 | 0.0000 | 0.0912 | 0.5457 | 2.0320 | |||
| BT-483 | HR+ | Luminal | (Z)-4-Hydroxytamoxifen | ESR1 | 7801.016 | uM | 22.32320 | 38.86550 | -0.9618 | -1.0000 | 1.9813 | 0.3751 | 0.8751 | 0.4118 | ||
| MCF7 | HR+ | Luminal | Ibandronate | FDPS | 10997.143 | uM | 51.06540 | 69.06960 | -0.8090 | -0.7856 | 3.1269 | 0.3990 | 0.9978 | 0.6416 | ||
| SK-BR-3 | HER2amp | Luminal | Torkinib | 15356.211 | uM | 0.00125 | 0.00492 | -0.3826 | -0.3333 | 0.3720 | 0.8953 | 0.9717 | 1.3112 | |||
| HCC1395 | TNBC | Basal B | Glycyl-H-1152 | ROCK2 | 12084.16 | uM | 12.49510 | 36.59980 | -0.0127 | -0.6415 | 0.7681 | 0.1579 | 0.9673 | 1.1178 | ||
| HCC1395 | TNBC | Basal B | Glycyl-H-1152 | ROCK2 | 12000.169 | uM | 5.15510 | 75.12560 | -0.0066 | -1.0000 | 0.4101 | 0.2688 | 0.9786 | 0.8565 |